Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 18;6:12. doi: 10.1038/s41541-020-00273-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Subcutaneous SMA560 tumor growth in mice (n = 7) following therapeutic immunization on days 1 and 8 with poly(I:C) alone, Odc1^{MHC I}, or Odc1^29mer SLP. b IFNγ ELISpot: splenocyte response to Odc1^{MHC I} 7 days following immunization with poly(I:C) alone, Odc1^{MHC I}, or Odc1^29mer SLP (n = 3). One-way ANOVA with post hoc Tukey’s test. c Subcutaneous SMA560 tumor growth in mice (n = 7) following therapeutic immunization on days 1 and 8 with poly(I:C) alone or Odc1^29mer SLP in the context of CD8+ depleting antibody or isotype control (antibody administration denoted by arrowheads). d IFNγ ELISpot: Odc1^29mer-mediated immune response to the Odc1^{MHC I}-restricted neoepitope or 29mer immunizing peptide in the context of CD8-depletion, CD4-depletion, or isotype-treated control (n = 3). Two-way ANOVA with Bonferroni post hoc test. e IFNγ ELISpot: splenocyte response to Odc1^{MHC I} 7 days following immunization with Odc1^29mer SLP in the context of CD40L-blocking antibody or isotype control (n = 3). Isotype vs. αCD40L, two-sample t test. f Subcutaneous SMA560 tumor growth in mice (n = 7) following therapeutic immunization on days 1 and 8 with poly(I:C) alone or Odc1^29mer in the context of CD40L-blocking antibody or isotype control (antibody administration denoted by arrowheads). For tumor growth data, error bars = mean ± s.e.m.; for ELISpot data, errors bars = mean ± s.d.